Kiniksa Pharmaceuticals International, plcNASDAQ: KNSA

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

· Issued by Kiniksa Pharmaceuticals International, plc
  • Primary and all major secondary efficacy endpoints were highly statistically significant
  • Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p

Kiniksa Pharmaceuticals International, plc on 6ix

In the deck

Story so far

Earlier from Kiniksa Pharmaceuticals International

Later from Kiniksa Pharmaceuticals International

All Kiniksa Pharmaceuticals International news releases